Clozapine re-exposure after dilated cardiomyopathy

Publication date

2017-05-27

Authors

Nederlof, Mariëtte
Benschop, Theo Wj
de Vries Feyens, Cornelia Adriana
Heerdink, RobORCID 0000-0002-5946-7209ISNI 0000000394315283

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

No license information available

Abstract

A 63-year-old woman with diabetes type II and a history of breast cancer was treated with clozapine for her refractory schizophrenia. She developed a dilated cardiomyopathy with an ejection fraction of 25%, a life-threatening event. The cause of heart failure could be multifactorial, with clozapine, family history, chemotherapy, diabetes type II and/or lithium as possible contributing risk factors. Clozapine was discontinued and the patient was referred to a hospice. Two weeks later, her heart failure slowly improved. Subsequently, she became extremely psychotic with a severe decline in quality of life. Therefore, it was decided to restart clozapine under cardiac monitoring. The patient's psychotic symptoms improved and her heart failure status remained stable for more than a year. Thereafter, a small deterioration was seen in cardiac function. In this case, re-exposure to clozapine was successful for at least 2 years.

Keywords

Taverne, SDG 3 - Good Health and Well-being

Citation

Nederlof, M, Benschop, T W, de Vries Feyens, C A & Heerdink, E R 2017, 'Clozapine re-exposure after dilated cardiomyopathy', BMJ Case Reports, vol. 2017, 219652. https://doi.org/10.1136/bcr-2017-219652